Brooks Laboratories Limited (NSE:BROOKS) — Market Cap & Net Worth
Market Cap & Net Worth: Brooks Laboratories Limited (BROOKS)
Brooks Laboratories Limited (NSE:BROOKS) has a market capitalization of $21.66 Million (Rs2.00 Billion) as of June 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #24872 globally and #1381 in its home market, demonstrating a 0.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Brooks Laboratories Limited's stock price Rs68.00 by its total outstanding shares 29457248 (29.46 Million). Review Brooks Laboratories Limited (BROOKS) total liabilities to assess the company's total debt and financial obligations.
Brooks Laboratories Limited Market Cap History: 2015 to 2026
Brooks Laboratories Limited's market capitalization history from 2015 to 2026. Data shows change from $29.47 Million to $21.66 Million (-0.85% CAGR).
Brooks Laboratories Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Brooks Laboratories Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
Brooks Laboratories Limited's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $42.21 Million | $800.09 Million | $106.33 Million | 0.05x | 0.40x |
| 2017 | $35.89 Million | $575.40 Million | $19.57 Million | 0.06x | 1.83x |
| 2018 | $19.34 Million | $557.12 Million | -$138.13 Million | 0.03x | N/A |
| 2019 | $9.24 Million | $550.30 Million | -$148.05 Million | 0.02x | N/A |
| 2020 | $21.17 Million | $691.33 Million | -$243.76 Million | 0.03x | N/A |
| 2021 | $31.62 Million | $770.68 Million | -$193.75 Million | 0.04x | N/A |
| 2022 | $34.82 Million | $911.85 Million | -$193.13 Million | 0.04x | N/A |
| 2023 | $45.75 Million | $624.80 Million | -$209.00 Million | 0.07x | N/A |
| 2024 | $57.39 Million | $794.86 Million | -$195.92 Million | 0.07x | N/A |
| 2025 | $25.53 Million | $825.57 Million | -$99.67 Million | 0.03x | N/A |
Competitor Companies of BROOKS by Market Capitalization
Companies near Brooks Laboratories Limited in the global market cap rankings as of June 19, 2026.
Key companies related to Brooks Laboratories Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Brooks Laboratories Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Brooks Laboratories Limited's market cap moved from $29.47 Million to $ 21.66 Million, with a yearly change of -0.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs21.66 Million | -15.15% |
| 2025 | Rs25.53 Million | -55.51% |
| 2024 | Rs57.39 Million | +25.45% |
| 2023 | Rs45.75 Million | +31.38% |
| 2022 | Rs34.82 Million | +10.13% |
| 2021 | Rs31.62 Million | +49.36% |
| 2020 | Rs21.17 Million | +129.14% |
| 2019 | Rs9.24 Million | -52.22% |
| 2018 | Rs19.34 Million | -46.12% |
| 2017 | Rs35.89 Million | -14.98% |
| 2016 | Rs42.21 Million | +43.24% |
| 2015 | Rs29.47 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Brooks Laboratories Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.66 Million USD |
| MoneyControl | $21.66 Million USD |
| MarketWatch | $21.66 Million USD |
| marketcap.company | $21.66 Million USD |
| Reuters | $21.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Brooks Laboratories Limited
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and d… Read more